Medium-term effects of bisoprolol administration on renal hemodynamics and function in mild to moderate essential hypertension

• Published in: Advances in therapy Vol. 24; no. 6; pp. 1260 - 1270
• Main Authors: Paterna, Salvatore, Parrinello, Gaspare, Di Pasquale, Pietro, Torres, Daniele, La Rocca, Gabriella, Antona, Roberta, Vernuccio, Laura, Fornaciari, Ersilia, Tarantino, Antonina, Piccione, Ercole, Fasullo, Sergio, Licata, Giuseppe
• Format: Journal Article
• Language: English
• Published: United States 01.11.2007
• Subjects: Adrenergic beta-Antagonists - administration & dosage; Adrenergic beta-Antagonists - therapeutic use; Adult; Antihypertensive Agents - administration & dosage; Antihypertensive Agents - therapeutic use; Bisoprolol - administration & dosage; Bisoprolol - therapeutic use; Blood Pressure - drug effects; Drug Administration Schedule; Female; Health technology assessment; Humans; Hypertension - drug therapy; Hypertension - physiopathology; Kidney Function Tests; Male; Middle Aged; Renal Circulation - drug effects
• ISSN: 0741-238X; 1865-8652
• DOI: 10.1007/BF02877772

Arterial hypertension is a significant cause of end-stage renal failure; effective treatment of hypertensive patients reduces the rate of progression of this disorder. ss-Blockers, particularly nonselective agents, are associated with deterioration of renal function in patients with chronic renal failure. Previous studies on the interaction of the beta1-selective adrenergic antagonist bisoprolol with kidney function have been performed only acutely and over the short term. This study was designed to evaluate the antihypertensive efficacy and effects on renal hemodynamics and function of bisoprolol during medium-term (6 mo) treatment of patients with mild to moderate essential hypertension. After a 2-wk run-in period on placebo, 87 consecutive hypertensive patients (46 men, 41 women) according to ESH-ESC (European Society of Hypertension/European Society of Cardiology) guidelines, aged from 27 to 64 y (mean age, 50+/-11 y), without renal or cardiovascular disease, were enrolled and assigned to treatment with bisoprolol 5 mg once daily for 6 mo. At recruitment and at 6 mo after treatment, renal function was assessed and renal hemodynamics evaluated in all patients through radioisotope studies. The medium-term effects of bisoprolol included a significant reduction in blood pressure and heart rate (P<.001) without significant adverse drug reactions. Moreover, bisoprolol produced no alteration in renal function or hemodynamics, or in cardiac output. Data presented here indicate that bisoprolol 5 mg given once daily to treat patients with mild to moderate essential hypertension is effective and safe for treatment and for preservation of renal performance when given on a medium-term basis.